In the slow erosion of brain tissue caused by reduced blood flow, neurons do not simply fail — they are undone by a precise biochemical cascade involving iron accumulation and lipid damage. Researchers have now traced a countervailing pathway, a molecular chain of events in which a single protein triggers the formation of a circular RNA, which in turn produces an enzyme that unlocks the brain's own defenses against this form of cell death. The discovery, made in mouse models of chronic cerebral ischemia, does not yet promise a cure, but it offers something equally valuable: a map of the machin
Scientists identify molecular pathway that protects brain cells during stroke
A protein that unlocks the brain's own defense against cell death
Mark
So this is about a protein that protects brain cells when blood flow is cut off. But the mechanism sounds incredibly intricate. Why does it matter that it works through this particular chain of events rather than some simpler pathway?
Mimi
Because if you want to develop a drug, you need to know exactly what to target. If you just knew "ferroptosis is bad," you'd be shooting in the dark. But now you know that IGF2BP3 is the entry point, that circRNA Dock1 is the messenger, that DOCK1-704aa is the active kinase. Each of those is a potential drug target. You could amplify the pathway, or you could intervene at any step.
Luke
But here's what I want to flag: this was all done in mouse models. We don't know yet if the same pathway operates in human brains, or if it operates the same way. The confidence is high for what happened in the mice, but the translation to humans is still an open question.
Mark
Fair point. So what would it take to know if this matters for actual patients?
Mimi
You'd need to look at human brain tissue from stroke patients, or run clinical trials testing whether you can activate this pathway therapeutically. You'd also need to understand whether ferroptosis is actually a major driver of damage in human chronic ischemia, or whether it's one factor among many.
Luke
And you'd need to know what happens if you artificially boost this pathway. Does it have side effects? Does it interfere with other cellular processes? The mice tolerated it fine, presumably, but that doesn't guarantee safety in humans.
Mark
So this is a discovery that opens a door, but the door hasn't been walked through yet.
Mimi
Exactly. It's a map of a mechanism. The clinical application is still ahead.
Le Pouls
- Chronic cerebral ischemia kills neurons slowly through ferroptosis — an iron-driven, lipid-damaging process that has long resisted precise therapeutic targeting.
- The key tension lies in a transcription factor, TCF21, that actively suppresses the brain's own ferroptosis defenses under ischemic stress, leaving neurons vulnerable.
- Researchers have identified a four-step molecular relay — IGF2BP3 protein to circular RNA to a kinase enzyme to TCF21 — that neutralizes this suppression and switches on protective genes.
- The pathway works not by activating new genes from scratch, but by repurposing the cell's splicing machinery to generate a circular RNA that would not otherwise exist.
- Findings are currently limited to mouse models, and whether the same axis operates in human brains — or can be safely manipulated — remains an open and urgent question.
In the slow erosion of brain tissue caused by reduced blood flow, neurons do not simply fail — they are undone by a precise biochemical cascade involving iron accumulation and lipid damage. Researchers have now traced a countervailing pathway, a molecular chain of events in which a single protein triggers the formation of a circular RNA, which in turn produces an enzyme that unlocks the brain's own defenses against this form of cell death. The discovery, made in mouse models of chronic cerebral ischemia, does not yet promise a cure, but it offers something equally valuable: a map of the machinery that keeps neurons alive under siege.
When blood flow to the brain diminishes over time, neurons face a slow and particular form of destruction driven by iron accumulation and lipid damage — a process known as ferroptosis. Scientists have long understood that ferroptosis worsens outcomes in chronic cerebral ischemia, but the precise molecular machinery capable of stopping it remained unclear.
A research team working with mouse models has now charted a protective pathway centered on a protein called IGF2BP3. When ischemia occurs, IGF2BP3 binds to the Dock1 gene and triggers an unusual splicing event: the gene's RNA folds backward into a circular form, producing a protein — DOCK1-704aa — that functions as a kinase, an enzyme that chemically modifies other proteins.
Its target is TCF21, a transcription factor that, under normal ischemic stress, suppresses two critical defense genes, Gpx4 and Fsp1, which protect cells from the very damage ferroptosis inflicts. When DOCK1-704aa phosphorylates TCF21 at a specific site, that suppression is lifted. The defense genes activate. Ferroptosis is held back. Brain damage is reduced.
What distinguishes this discovery is the nature of the pathway itself — a chain of post-transcriptional and post-translational handoffs that hijacks existing cellular machinery rather than requiring entirely new gene activation. Each step is specific, each one necessary.
The findings remain rooted in animal models, and whether this axis functions identically in human brains is yet to be established. Still, the identification of this precise molecular sequence — from IGF2BP3 through circular RNA to a kinase to a transcription factor to ferroptosis defense — gives researchers a concrete target to study, test, and potentially harness for patients facing ischemic brain injury.
When blood flow to the brain slows or stops, neurons face a particular kind of death. It is not the sudden catastrophe of a major stroke, but a slower unraveling driven by iron accumulation and lipid damage—a process scientists call ferroptosis. For years, researchers understood that this form of cell death worsened outcomes in chronic cerebral ischemia, the condition where reduced blood supply damages brain tissue over time. What remained opaque was the precise machinery that might stop it.
A team of researchers working with mouse models of cerebral ischemia has now mapped a protective pathway that shields neurons from ferroptosis. The discovery centers on a protein called IGF2BP3, which acts as a molecular gatekeeper. When cerebral ischemia occurs, IGF2BP3 binds to specific sequences within the Dock1 gene and triggers an unusual event: the gene's RNA is spliced backward into a circular form rather than the typical linear one. This circular RNA, called circRNA Dock1, carries instructions for a protein of 704 amino acids—DOCK1-704aa—that functions as a kinase, an enzyme that adds phosphate groups to other proteins.
The target of this kinase is a transcription factor named TCF21. Under normal ischemic stress, unmodified TCF21 acts as a brake on survival, actively suppressing the expression of two critical ferroptosis defense genes: Gpx4 and Fsp1. These genes encode proteins that protect cells from the iron and lipid damage that drives ferroptosis. When DOCK1-704aa phosphorylates TCF21 at a specific location—serine 116—the transcription factor loses its repressive grip. The defense genes switch on. Ferroptosis is held at bay. Brain damage is reduced.
What makes this discovery significant is not merely that a protective pathway exists, but that it operates through a chain of post-transcriptional and post-translational events—modifications that happen after genes are transcribed and proteins are made. The pathway does not require new genes to be activated from scratch. Instead, it hijacks the splicing machinery to create a circular RNA that would not normally exist, which then produces a protein that modifies another protein, which in turn unlocks a transcriptional program. It is a network of precise molecular handoffs, each one necessary, each one specific.
The research was conducted in mouse models of chronic cerebral ischemia, meaning the findings describe what happens in laboratory animals under controlled conditions. Whether this same pathway operates identically in human brains, or whether it could be therapeutically targeted without unintended consequences, remains to be determined. But the identification of this axis—IGF2BP3 to circRNA Dock1 to DOCK1-704aa to TCF21 to ferroptosis defense genes—provides a concrete molecular target for future investigation. Researchers now have a specific mechanism to study, to test, and potentially to manipulate. The next phase will be determining whether this pathway can be harnessed to protect brain tissue in human patients facing chronic ischemia or other conditions where ferroptosis contributes to neuronal death.
Citations marquantes
IGF2BP3 suppresses neuronal ferroptosis through a specific IGF2BP3/circRNA Dock1/TCF21 signaling axis— Study findings
Envie de l'histoire complète ?
Lire l'original sur Nature ↗
Culture & Arts